Replies to post #355667 on Innovation Pharmaceuticals Inc (IPIX)

[Lemoncat]

No I don't. I'm confident Merck's M&A team can add up to the fact that three years of Cubicin sales won't equal $9.5B before the patent expired and had other reasons for acquiring the rest of the pipeline at that price.

Then again, I do know one CEO who couldn't understand how the ABX market would look once Cubicin went generic. So anything is possible.

But I'm reasonably sure the 5th largest pharma company in the world can do basic math and DD on revenue vs patent expiration. They have large teams of people dedicated to this rather than a CPA and an upstart Veterinarian.

Go IPIX!